Industry's Cure For Biomarker Development Woes: Standards, Transparency, Incentives
Executive Summary
Panelists at BIO also said FDA should leverage external expertise in designing biomarker development programs and adopt an advisory committee approach to reviewing qualification packages.
You may also be interested in...
Biomarkers Qualification: Can FDA Get Rolling Before A Push From Congress?
FDA has been reluctant to lay out evidentiary standards for biomarker qualification, but its call for information on promising candidates may be an initial step toward creating such a framework.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.